TY - BOOK ID - 135755761 TI - Adverse Events : Race, Inequality, and the Testing of New Pharmaceuticals PY - 2020 SN - 147986143X PB - New York : New York University Press, DB - UniCat KW - validity. KW - study compensation. KW - social world. KW - social network. KW - social inequality. KW - social inequalities. KW - serial participation. KW - screen failure. KW - risk. KW - research staff. KW - research participation. KW - reputation. KW - region. KW - race. KW - qualifying. KW - public health. KW - profit. KW - phase I. KW - phase I trials. KW - phase I industry. KW - phase I clinical trials. KW - pharmaceutical industry. KW - participation. KW - opportunism. KW - model organism. KW - methods. KW - informed consent. KW - inclusion-exclusion criteria. KW - United States. KW - clinic. KW - clinical trial culture. KW - clinical trials. KW - clinics. KW - confinement. KW - consumption. KW - decision making. KW - demographics. KW - drug development. KW - economic interests. KW - economic motivations. KW - economic need. KW - economic risk. KW - epistemology. KW - health-promoting behavior. KW - healthy volunteers. KW - identity. KW - imbricated stigma. KW - Equality. UR - https://www.unicat.be/uniCat?func=search&query=sysid:135755761 AB - Explores the social inequality of clinical drug testing and its effects on scientific resultsImagine that you volunteer for the clinical trial of an experimental drug. The only direct benefit of participating is that you will receive up to. ER -